Prion Protein as a Receptor for Amyloid-Beta Oligomers
US-2016176972-A1 · Jun 23, 2016 · US
Method for treating a neurodegenerative disease by administering an anti-cellular prion protein (PrPc) antibody
US12110336B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12110336-B2 |
| Application number | US-202017020247-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 14, 2020 |
| Priority date | Apr 15, 2016 |
| Publication date | Oct 8, 2024 |
| Grant date | Oct 8, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure provides antibodies and antigen-binding fragments capable of binding PrPC. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
First claim
Opening claim text (preview).
We claim: 1. A method for treating a neurodegenerative disorder in a subject in which aberrant PrP c activity is involved, comprising: administering to the subject a pharmaceutically effective amount of an antibody or an antigen-binding fragment comprising a light chain variable (VL) domain and a heavy chain variable (VH) domain, wherein the VH domain comprises: a VH CDR 1 having the amino acid sequence of SEQ ID NO: 5; a VH CDR2 having the amino acid sequence of SEQ ID NO: 6; and a VH CDR3 having the amino acid sequence of SEQ ID NO: 7; and the VL domain comprises: a VL CDR1 having the amino acid sequence of SEQ ID NO: 14; a VL CDR2 having the amino acid sequence of SEQ ID NO: 15; and a VL CDR3 having the amino acid sequence of SEQ ID NO: 16; and wherein the neurodegenerative disorder is one of: Alzheimer's Disease, disease associated with misfolded PrP, Creutzfeldt-Jakob Disease, Gerstmann-Sträussler-Schenker Disease, Fatal Familial Insomnia, bovine spongiform encephalopathy, scrapie, chronic wasting disease, transmissible mink encephalopathy, and feline spongiform encephalopathy. 2. The method of claim 1 , wherein the subject is a human or a non-human animal.
Assignees
Inventors
Classifications
Single chain antibody (scFv) · CPC title
Fab or Fab' · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12110336B2 cover?
- The present disclosure provides antibodies and antigen-binding fragments capable of binding PrPC. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
- Who is the assignee on this patent?
- Medimmune Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2872. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).